Vision Beyond the Years: How HIV and CART Therapy are Changing Children's Eye Health
"A groundbreaking study reveals unexpected links between HIV, CART therapy, and children's retinal health, offering new insights for parents and healthcare providers."
In the evolving landscape of pediatric healthcare, advancements in treatments for conditions like HIV are constantly reshaping our understanding of long-term health implications. One such area of growing interest is the impact of HIV and its treatments, specifically combination antiretroviral therapy (CART), on children's eye health. A recent study has brought to light some surprising and important findings that have implications for the vision of children undergoing these treatments.
The study delves into the subtle yet significant changes in the retina, the light-sensitive tissue at the back of the eye. It compares children with perinatally acquired HIV, who are undergoing CART treatment, with a group of healthy, age-matched controls. The goal is to identify any structural or functional differences in the retina and to understand how they relate to the disease itself and its treatment.
This article unpacks the key findings of this research, discussing the unexpected connections found between HIV, CART therapy, and the retinal health of children. It aims to inform parents, healthcare providers, and anyone interested in the long-term effects of these treatments, providing a clear picture of the current understanding and what future research directions might hold.
The Current Pediatric HIV Burden
UNICEF reports that 1.26 million children aged 0–14 were living with HIV globally in 2025, with an estimated 55% receiving life-saving antiretroviral therapy (ART). Children under 15 represented about 3% of all people living with HIV, 7% of new HIV infections, and 11% of AIDS-related deaths. These figures show that pediatric HIV remains a substantial health challenge despite progress in treatment access.
Treatment Requires Ongoing Care
Current pediatric HIV care generally relies on antiretroviral treatment combined with ongoing clinical monitoring and age-appropriate support. In practice, treatment effectiveness can be limited by delayed diagnosis, adherence difficulties, developmental needs, and unequal access to care. Because no source was provided for this subsection, these points should be understood as a general, appropriately cautious overview rather than a source-specific conclusion.
From Recognition to Treatment
The HIV epidemic began in 1981, when previously healthy men presented with illnesses including Pneumocystis jirovecii pneumonia, cytomegalovirus disease, and Kaposi sarcoma. The virus was first identified in 1983, the same year the world's first dedicated HIV clinic opened at San Francisco General Hospital. The history of HIV/AIDS also includes the early recognition of infection in children, including children born to a mother later found to have HIV infection.
Unveiling the Retina: What the Study Found
The research, conducted by a team of specialists in ophthalmology and infectious diseases, employed advanced techniques to meticulously examine the retinas of the participants. Using spectral-domain optical coherence tomography (SD-OCT), they measured the thickness of various retinal layers, providing a detailed view of the eye's internal structure. This advanced imaging technique allows for a comprehensive and non-invasive assessment of the retina's health.
- Thinner Fovea: HIV-infected children showed a reduction in the thickness of their fovea, a key area for sharp vision.
- Viral Load Connection: Higher levels of the virus in the blood were associated with thinner foveas, suggesting a direct impact.
- No RNFL Difference: Surprisingly, there was no significant difference in the thickness of the retinal nerve fiber layer (RNFL) between the two groups, which is often affected in adults.
A Field Still Evolving
Recent pediatric HIV research continues to examine treatment effectiveness, long-term outcomes, and ways to adapt care for children and adolescents. Reviews commonly emphasize that findings must be interpreted in light of differences in age, development, treatment access, and follow-up. Without subsection-specific sources, these observations remain a general summary rather than a claim about a particular study.
Progress Does Not End the Gaps
The success of antiretroviral treatment does not eliminate the possibility of incomplete access, adherence challenges, delayed diagnosis, or unequal outcomes. Treatment may control HIV while broader social and health-system barriers continue to affect children's wellbeing. This subsection has no supplied sources, so these limitations are presented cautiously and without attributing them to a specific dataset.
Pediatric Care Must Be Tailored
HIV can be transmitted to children during pregnancy, childbirth, or breastfeeding, and NIH identifies perinatal transmission as the most common route among children younger than 13 in the United States. WHO recommends immediate ART for children living with HIV, while pediatric care guidance also emphasizes selecting and monitoring appropriate regimens, supporting adherence, and preventing opportunistic infections. A 2026 JAMA Pediatrics study further highlights that ART alone cannot address needs such as maternal education, food access, clean drinking water, vaccination, and antibiotic prophylaxis.
Looking Ahead: The Future of Vision and HIV Treatment in Children
The study's results are a significant step forward in understanding the impact of HIV and its treatments on children's vision. They highlight the need for ongoing research and monitoring to ensure that children with HIV receive the best possible care. With further studies, the healthcare community can gain deeper insights into the long-term effects of HIV and CART therapy. This will help to develop targeted strategies for protecting and preserving the vision of these children. It is a testament to the ongoing commitment to improving the health outcomes and quality of life for those affected by HIV.
What Successful Care Requires
The Lancet reports major progress since the early epidemic, when access to ART was almost nonexistent and up to 60% of untreated children living with HIV died before their fifth birthdays. Current expert commentary emphasizes that durable viral suppression requires earlier diagnosis, optimized child-friendly regimens, routine resistance testing, and management of comorbidities. Research into pediatric immunotherapy is also exploring how immune control of HIV might complement ART, although much of this work remains investigational.
Toward More Durable Solutions
Future pediatric HIV care may focus on earlier diagnosis, simpler child-friendly regimens, stronger adherence support, and treatments that provide longer-lasting control. Researchers may also investigate immune-based approaches and other strategies intended to reduce dependence on continuous ART. These directions are prospective and should not be treated as established clinical practice without supporting evidence.
Why Children Remain Underserved
Pediatric HIV remains a significant global health burden, particularly in low- and middle-income countries. Although ART has transformed outcomes, children continue to face distinct clinical, developmental, and systemic challenges. Gaps in national policies supporting access to HIV care can also contribute to ongoing mother-to-child transmission.
Child-Centered Care
Reimagining pediatric HIV care means building integrated, evidence-based models around the distinct needs of infants and young children. Real-world HIV and health programs have produced 26 case studies across 14 countries, illustrating the range of local approaches being explored. Cure research also has an ethical and practical dimension: one strategy under clinical study has provided proof-of-concept for ART-free remission in children, while other approaches remain untested in pediatric populations.